Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Pharmgen Science Inc. (004720:KRX), powered by AI.
Pharmgen Science Inc. is currently trading at ₩3,140. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Pharmgen Science Inc. on Alpha Lenz.
Pharmgen Science Inc.'s P/E ratio is -0.6.
“Pharmgen Science Inc. trades at a P/E of -0.6 (undervalued) with modest ROE of -58.9%.”
Ask for details →Pharmgen Science Inc. is a prominent player in the pharmaceutical industry, concentrating on the development, production, and commercialization of a wide array of medicinal products. The company's primary function is to advance medical science and improve healthcare outcomes by discovering new drug compounds and enhancing existing therapies. Pharmgen Science Inc. positions itself at the forefront of biopharmaceutical innovation, engaging in extensive research and development efforts to address unmet medical needs across various therapeutic areas. Notable for its rigorous scientific approach, Pharmgen Science Inc. impacts the healthcare sector significantly by providing cost-effective and efficient pharmaceutical solutions. Its product portfolio may encompass prescription medications, over-the-counter drugs, and possibly biotechnological developments. The company's operations contribute to the broader healthcare landscape, supporting patient health and wellness while also stimulating medical research growth. In the broader market, Pharmgen Science Inc. plays a vital role by partnering with healthcare providers, regulatory agencies, and research institutions to ensure effective distribution and regulatory compliance of its products. With a commitment to innovation and quality, Pharmgen Science Inc. remains a central figure in advancing global healthcare solutions.
“Pharmgen Science Inc. trades at a P/E of -0.6 (undervalued) with modest ROE of -58.9%.”
Ask for details →Pharmgen Science Inc. (ticker: 004720) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - General). It has approximately 226 employees. Market cap is $71.1B.
The current price is ₩3,140 with a P/E ratio of -0.61x and P/B of 0.49x.
ROE is -58.95% and operating margin is 3.46%. Annual revenue is $173.1B.